Navigation Links
Evalve MitraClip: Clinical trial of nonsurgical repair for severe mitral valve regurgitation
Date:6/19/2008

LOS ANGELES (June 18, 2008) -- The Cedars-Sinai Heart Institute is the lead enroller in the world for the Everest II Clinical Trial a study comparing non-surgical repair for severe mitral valve regurgitation with conventional surgery. In 2005, a team of doctors at the Institute implanted the first Evalve MitraClip in California, and was also first on the West Coast to insert two clips during a single procedure. Cedars-Sinai is believed to be the most experienced center in the nation with any form of percutaneous mitral valve repair.

About four million Americans have significant mitral valve regurgitation, with 250,000 new patients diagnosed each year.

The mitral valve consists of two "leaflets" that act as swinging doors between the left atrium and the left ventricle. If the valve fails to close properly, blood flows backward into the atrium (regurgitation), leaving the left ventricle, the heart's primary pumping chamber, with too little blood. To compensate, the ventricle stretches and overworks. Over time, it undergoes a process called remodeling, becoming enlarged, distorted and weak.

The MitraClip procedure is performed in a cardiac catheterization laboratory with the patient under general anesthesia. A thin, flexible tube (catheter) is inserted through a small incision in the groin and guided through the femoral vein to the affected area of the heart. A smaller catheter holding the clip is slipped through the first catheter. After the clip is attached to the valve leaflets, the catheters are removed. The patient is released from the hospital within a day or two.

While the procedure is complex and challenging, requiring a coordinated effort among echocardiographers, interventional cardiologists, anesthesiologists and other team members, it is also somewhat forgiving. If the clip is not placed ideally on the first attempt, it can be reset. If it does not sufficiently correct the regurgitation, surgical repair or replacement of the valve remains an option.

Results from studies so far show that the MitraClip can provide successful reduction of mitral regurgitation for up to 36 months. Also, studies showed that with resumption of proper valve function, left ventricular remodeling was significantly improved at 12-month follow-up.

Traditional surgery is still the best option in extremely difficult cases or when the annulus, the ring-shaped structure to which the leaflets are attached, needs repair. Cedars-Sinai's Center for Valvular Intervention, one of the largest heart valve programs in the western United States, combines the expertise of cardiologists and cardiothoracic surgeons to offer a wide range of surgical and non-surgical repair and replacement procedures.


'/>"/>

Contact: Sandy Van
sandy@prpacific.com
800-880-2397
Cedars-Sinai Medical Center
Source:Eurekalert

Related medicine news :

1. Correction: Evalve Announces CE Mark Approval of the Worlds First Percutaneous Valve Repair System
2. Evalve Announces CE Mark Approval of the Worlds First Percutaneous Valve Repair System
3. Edwards Lifesciences Initiates Patent Infringement Litigation Against CoreValve in the U.S.
4. UPDATED: Evalve(R) Completes $60 Million Series D Financing
5. Evalve(R) Completes $60 Million Series D Financing
6. Effective Communication of Clinical Studies for Maximum Impact
7. Ease-of-Use and Intuitive Nature of the DATATRAK eClinical(TM) Platform Allows for Further Operational Efficiencies
8. INACSL and Elsevier partner to publish Clinical Simulation in Nursing
9. Winning Method - Effective Identification and Development of Clinical Investigators
10. Abatacept and infliximab improve clinical response over time in methotrexate-refractory RA patients
11. New insight into RA patient priorities and motivators for clinical trial involvement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... Ongoing news ... Aging Life Care Association™ (ALCA) to conduct a survey that takes a closer look ... released today illustrates the prevalence and causes of TBI among the aging population, and ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... welcomes S.S. Nesbitt as the latest addition to its growing list of Partner ... locations throughout the Southeast, from Orlando to Huntsville and in between. , Harnessing ...
(Date:2/10/2016)... ... February 10, 2016 , ... AxoGen, Inc. (NASDAQ: AXGN), a leading ... the fourth quarter and full year ended December 31, 2015 on Monday, February 29, ... webcast for the investment community following the release at 4:30 PM ET. Investors interested ...
(Date:2/10/2016)... ... February 10, 2016 , ... AHRA: The Association ... inspirational speaker Jan Fox will serve as keynote speaker at the organization’s 2016 ... with tools to more effectively communicate with their own organizational staff and leadership. ...
(Date:2/10/2016)... ... February 10, 2016 , ... For additional information contact Phyllis Strupp 480-488-5858 , ... with Age: The Ultimate Guide to Brain Training" by award-winning author Phyllis Strupp ... publication date is March 16, 2016. A free review copy is available to ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... 9, 2016 On Tuesday, February ... met with its Arthritis Advisory Committee to ... Johnson & Johnson,s Remicade and most likely ... the U.S. The Biologics Prescribers Collaborative (BPC) ... Alliance for Patient Access, American Association of ...
(Date:2/10/2016)... February 10, 2016 The campaign aims ... 5 years reach the milestone of their 5 th ... ensure 2,50,532 children between the ages of 2 - 5 ... --> The campaign aims to ... reach the milestone of their 5 th birthday   ...
(Date:2/9/2016)... FARMINGDALE, N.Y., Feb. 9, 2016  Misonix, Inc. ... company that designs, manufactures and markets innovative therapeutic ... wound debridement, cosmetic surgery, laparoscopic surgery and other ... second quarter and the first half of fiscal ... --> --> Highlights ...
Breaking Medicine Technology: